All In Biotech

Drug Trial Radar · NCT07219654

Efficacy and Safety Study of TPX-115 on Partial-thickness Rotator Cuff Tear

A Phase 2, Double-blinded, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Allogeneic Dermal Fibroblasts (TPX-115) in Patients With Partial-thickness Rotator Cuff Tear

Last checked: Nov 20, 2026Latest source record: Jun 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Jun 9, 2026

Primary completion

May 2027

Study completion Nov 2027

Sponsor

Lead sponsor
Tego Science, Inc.Industry
Sponsor type
Industry
First posted
Oct 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this study is to evaluate the efficacy and safety of allogeneic dermal fibroblasts (TPX-115) compared to placebo in patients with Partial-Thickness Rotator Cuff Tear(PTRCT). Primary endpoint is to evaluate the efficacy of TPX-115 compared to placebo, as measured by improvement in the Constant-Murley Score (CMS) in patients with PTRCT. Secondary endpoints are: * To evaluate functional (including shoulder pain) and structural improvements in the affected shoulder after administration of TPX-115 compared to placebo in patients with PTRCT * To evaluate the safety and tolerability of TPX-115 in patients with PTRCT * To assess the immunogenicity of TPX-115

Conditions

  • Partial Thickness Rotator Cuff Tears

Interventions

  • TPX-115Biological

    Single injection of Allogeneic dermal fibroblasts (TPX-115) via ultrasound-guided intratendinous injection

  • Cryopreserving hyaluronic acid mediumOther

    Medium included in TPX-115 for cryopreservation

  • SalineDrug

    Saline

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in Constant-Murley Score(CMS) at Week 24Time frame: Baseline, Week 24

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • BioSolutions Clinical Research Center

    La Mesa, California · Recruiting

  • Sports & Orthopedic Center - Advanced Research

    Deerfield Beach, Florida · Active not recruiting

  • Rush University Medical Center

    Chicago, Illinois · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.